Maze Therapeutics, Inc.
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $167.5M
- Net income
- -$131.1M
- Total assets
- $397.1M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $142.9M
- Operating income
- -$142.9M
- Income tax
- $0
- Net income
- -$131.1M
- EPS (basic)
- $-3.05
- EPS (diluted)
- $-3.05
Balance sheet
- Total assets
- $397.1M
- Current assets
- $349.7M
- Total liabilities
- $42.2M
- Current liabilities
- $22.6M
- Shareholders’ equity
- $355.0M
Cash flow
- Operating cash flow
- -$111.9M
- Investing cash flow
- -$171.0M
- Financing cash flow
- $275.3M
- Net cash flow
- -$7.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-3.05
- Shares outstanding
- 57.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 31, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $131.1M in FY2024.
- Trading 55% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Maze Therapeutics, Inc..
Write a review
News about Maze Therapeutics, Inc.
News & sentiment via Polygon.io
